MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No

被引：1
|
作者：
Ebers, George C. [1 ]
机构：
[1] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 03期
关键词：
LONG-TERM DISABILITY; INTERFERON BETA-1B; RELAPSES;
D O I：
10.1177/1352458513518264
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：282 / 283
页数：2
相关论文
共 50 条
  • [41] The effectiveness of Natalizumab on MRI outcome measures in patients with relapsing multiple sclerosis
    Dalton, C
    Barker, G
    MacManus, D
    Miszkiel, K
    Bates, D
    Blumhardt, L
    Hawkins, C
    Palace, J
    Sharief, M
    Swingler, R
    Young, C
    Miller, D
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (03): : 399 - 399
  • [42] Primary results of a phase-III, randomized controlled trial of the Behavioral Intervention for increasing Physical Activity in Multiple Sclerosis project
    Motl, Robert W.
    Kidwell-Chandler, Ariel
    Sandroff, Brian M.
    Pilutti, Lara A.
    Cutter, Gary R.
    Aldunate, Roberto
    Bollaert, Rachel E.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (03) : 415 - 426
  • [43] Linomide in the treatment of multiple sclerosis:: MRI results from prematurely terminated phase-III trials
    Tan, IL
    Lycklama à Nijeholt, GJ
    Polman, CH
    Adèr, HJ
    Barkhof, F
    MULTIPLE SCLEROSIS, 2000, 6 (02): : 99 - 104
  • [44] Outcome measures in childhood glaucoma: a systematic review of randomized controlled trials
    Sarohia, Gurkaran S.
    Elsayed, Maram E. A. Abdalla
    Solarte, Carlos Eduardo
    Hornby, Stella J.
    Brookes, John
    Chang, Ta Chen Peter
    Malik, Rizwan
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2023, 261 (09) : 2625 - 2639
  • [45] Outcome measures in childhood glaucoma: a systematic review of randomized controlled trials
    Gurkaran S. Sarohia
    Maram E. A. Abdalla Elsayed
    Carlos Eduardo Solarte
    Stella J. Hornby
    John Brookes
    Ta Chen Peter Chang
    Rizwan Malik
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2023, 261 : 2625 - 2639
  • [46] Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials - YES
    Kapoor, Raj
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (11) : 1454 - 1455
  • [47] Advanced MRI measures like DTI or fMRI should be outcome measures in future clinical trials - Commentary
    De Stefano, Nicola
    Giorgio, Antonio
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (11) : 1458 - 1460
  • [48] A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis
    Giovannoni, Gavin
    Knappertz, Volker
    Steinerman, Joshua R.
    Tansy, Aaron P.
    Li, Thomas
    Krieger, Stephen
    Uccelli, Antonio
    Uitdehaag, Bernard M. J.
    Montalban, Xavier
    Hartung, Hans-Peter
    Pia Sormani, Maria
    Cree, Bruce A. C.
    Lublin, Fred
    Barkhof, Frederik
    NEUROLOGY, 2020, 95 (08) : E1027 - E1040
  • [49] Randomized Controlled Trials of Rehabilitation in Multiple Sclerosis: Barriers and Unmet Needs
    Motl, Robert W.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (5_SUPPL) : 36 - 40
  • [50] Is placebo effect getting bigger in randomized controlled trials of multiple sclerosis?
    Emekli, A. S.
    Ersozlu, E.
    Kurtuncu, M.
    Gunduz, T.
    Eraksoy, M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 971 - 972
12345